Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;68(5):e28942.
doi: 10.1002/pbc.28942. Epub 2021 Feb 8.

Real-world case series and summary of current literature of infants and toddlers with severe hemophilia A with inhibitor on prophylaxis with emicizumab

Jessica Garcia  1   2 , Ayesha Zia  1   2
Affiliations
Review

Real-world case series and summary of current literature of infants and toddlers with severe hemophilia A with inhibitor on prophylaxis with emicizumab

Jessica Garcia et al. Pediatr Blood Cancer. 2021 May.

Abstract

Emicizumab is a recombinant, humanized, and a bispecific monoclonal antibody that bridges activated factor (F) IX and FX in place of FVIII to restore hemostasis in persons with hemophilia A (PHA). Data on the efficacy and safety of emicizumab in young children is limited. Immunologic naivety, physiologically decreased production of vitamin K dependent proteins, specifically FIX, and enhanced clearance of emicizumab in infants may support decreased emicizumab effectiveness. We report on the facilitation of care rendered by using emicizumab in young PHA with inhibitors and extend data on the efficacy and safety in PHA < 3 years.

Keywords: emicizumab; hemophilia A; infant; inhibitor; toddler.

PubMed Disclaimer

References

REFERENCES

    1. Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood. 2017;130(23):2463-2468.
    1. Young G, Liesner R, Chang T et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134(24):2127-2138.
    1. Medical Scientific Advisory Committee of the National Hemophilia Foundation (USA) MASAC document #258-Recommendation on the use and management of Emicizumab-kxwh (Hemlibra®) for hemophilia A with and without inhibitors. 2020. https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-andS... October 1, 2020.
    1. Barg AA, Avishai E, Budnik I, et al. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-single-center cohort. Pediatr Blood Cancer. 2019;66(11):e27886.
    1. McCary I, Guelcher C, Kuhn J, et al. Real-world use of emicizumab in patients with haemophilia A: bleeding outcomes and surgical procedures. Haemophilia. 2020;26:631-636.

LinkOut - more resources